NKTR
HEALTHCARENektar Therapeutics
$85.09+0.93 (+1.11%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving NKTR Today?
No stock-specific AI insight has been generated for NKTR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$7.99$109.00
$85.09
Fundamentals
Market Cap$2.9B
P/E Ratio—
EPS$-9.73
Dividend Yield—
Dividend / Share—
ROE-2.2%
Profit Margin-3.0%
Debt / Equity—
Trading
Volume568K
Avg Volume (10D)—
Shares Outstanding33.7M
NKTR News
48 articles- [8-K] NEKTAR THERAPEUTICS Reports Material EventStock Titan·May 9, 2026
- Nektar Therapeutics Establishes New Equity Distribution AgreementTipRanks·May 9, 2026
- Nektar Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- Earnings call transcript: Nektar Therapeutics Q1 2026 reveals strong cash position amid mixed stock responseInvesting.com Canada·May 8, 2026
- Nektar (NKTR) Q1 2026 Earnings TranscriptMotley Fool·May 7, 2026
- Nektar Therapeutics Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- How The Rezpegaldesleukin Story Is Recasting The Narrative For Nektar Therapeutics (NKTR)Yahoo Finance·May 2, 2026
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 1, 2026
- Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial MarketsYahoo Finance·Apr 28, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 28, 2026
- Nektar Therapeutics Shares 52-Week REZOLVE-AA Data as Rezpeg Boosts SALT ≤20 Responses in Alopecia AreataMarketbeat·Apr 25, 2026
- Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitGlobeNewswire Inc.·Apr 24, 2026
- Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesYahoo Finance·Apr 23, 2026
- Nektar Therapeutics Announces Pricing of Upsized $325 Million Public OfferingYahoo Finance·Apr 22, 2026
- ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTRGlobeNewswire Inc.·Apr 22, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQSTGlobeNewswire Inc.·Apr 21, 2026
- Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTRGlobeNewswire Inc.·Apr 21, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Eos Energy Enterprises, Inc. Of Class Action Lawsuit and Upcoming Deadlines – EOSEGlobeNewswire Inc.·Apr 21, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORTGlobeNewswire Inc.·Apr 21, 2026
- Nektar (NKTR) Moves 18.3% Higher: Will This Strength Last?Yahoo Finance·Apr 21, 2026
- Why Nektar Therapeutics Stock Rocked it TodayThe Motley Fool·Apr 20, 2026
- Nektar Therapeutics Adds To Its 129% Two-Month Run With Alopecia NewsYahoo Finance·Apr 20, 2026
- Nektar Therapeutics Announces Proposed Public OfferingYahoo Finance·Apr 20, 2026
- Sector Update: Health Care Stocks Fall Late AfternoonYahoo Finance·Apr 20, 2026
- Market Feels Weak, But Stocks Tell StoriesYahoo Finance·Apr 20, 2026
- This Biotech Stock Soars on Hair Loss Trial Results. It Isn’t a Cure for Baldness.Yahoo Finance·Apr 20, 2026
- Nektar surges again as alopecia drug shows new promise in extension studyBiopharmadive·Apr 20, 2026
- 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with RezpegaldesleukinYahoo Finance·Apr 20, 2026
- Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026Yahoo Finance·Apr 19, 2026
- ROSEN, LEADING TRIAL ATTORNEYS, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTRGlobeNewswire Inc.·Apr 19, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 17, 2026
- Bright Outlook for Nektar Therapeutics (NKTR) Hinges on Positive Trial ResultsYahoo Finance·Apr 17, 2026
- ROSEN, A LEADING NATIONAL FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTRGlobeNewswire Inc.·Apr 16, 2026
- DEADLINE ALERT for EOSE, SLNO, NKTR, DRVN: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsGlobeNewswire Inc.·Apr 16, 2026
- ROSEN, A LEADING AND RANKED FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTRGlobeNewswire Inc.·Apr 13, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 10, 2026
- Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitGlobeNewswire Inc.·Apr 8, 2026
- Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTRGlobeNewswire Inc.·Apr 7, 2026
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTRGlobeNewswire Inc.·Apr 6, 2026
Price Data
Open$85.00
Previous Close$84.16
Day High$86.33
Day Low$83.66
52 Week High$109.00
52 Week Low$7.99
52-Week Range
$7.99$109.00
$85.09
Fundamentals
Market Cap$2.9B
P/E Ratio—
EPS$-9.73
Dividend Yield—
Dividend / Share—
ROE-2.2%
Profit Margin-3.0%
Debt / Equity—
Trading
Volume568K
Avg Volume (10D)—
Shares Outstanding33.7M
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—